Status: retired, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2021. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3676208017 | Abacavir 300 mg and lamivudine 150 mg and zidovudine 300 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3676210015 | Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Is a | Product containing lamivudine (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Is a | Product containing zidovudine (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has active ingredient | Lamivudine (substance) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has active ingredient | Zidovudine (substance) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Is a | Product containing abacavir (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has active ingredient | Protease inhibitor | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has active ingredient | Abacavir (substance) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Is a | Abacavir sulfate + lamivudine + zidovudine | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has active ingredient | Abacavir sulfate (substance) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has manufactured dose form | Tablet | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Is a | Product containing abacavir and lamivudine and zidovudine (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has active ingredient | Abacavir (substance) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has manufactured dose form | Oral tablet | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Is a | Product containing zidovudine in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Is a | Product containing abacavir and lamivudine in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Is a | Lamivudine- and zidovudine-containing product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Lamivudine (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 150 | false | Inferred relationship | Some | 1 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 1 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Some | 1 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 300 | false | Inferred relationship | Some | 2 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 2 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 2 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Some | 2 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 300 | false | Inferred relationship | Some | 3 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 3 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 3 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Some | 3 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 300 | false | Inferred relationship | Some | 1 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has active ingredient | Lamivudine (substance) | false | Inferred relationship | Some | 3 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Lamivudine (substance) | false | Inferred relationship | Some | 3 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 150 | false | Inferred relationship | Some | 3 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has active ingredient | Zidovudine (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Zidovudine (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has active ingredient | Abacavir (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Abacavir (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Zidovudine (substance) | false | Inferred relationship | Some | 3 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has unit of presentation | Tablet (unit of presentation) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Is a | Product containing abacavir and lamivudine and zidovudine in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has precise active ingredient | Zidovudine (substance) | false | Inferred relationship | Some | 3 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has precise active ingredient | Lamivudine (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Has precise active ingredient | Abacavir (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Count of base of active ingredient | 3 | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Is a | Product containing only abacavir and lamivudine and zidovudine in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
| Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet | Plays role | Antiretroviral therapeutic role | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Concept inactivation indicator reference set
REPLACED BY association reference set (foundation metadata concept)
FHIR